Search

Objective: To evaluate the effect of continuous positive airway pressure (CPAP) treatment on metabolic syndrome and insuline resistance in patients with obstructive sleep apnea syndrome (OSAS). Materials and Methods: This study evaluated retrospectively with 30 patients who received OSAS diagnosis following polysomnography between the years January 2016 - January 2017, whose Respiratory Disturbance Index were above 15, and who were between the ages of 18-78, having no diabetes, chronic liver and kidney disease, malignancy and mental retardation. The anthropometric measures and blood values of these patients before the CPAP treatment and 3 months afterwards were evaluated in their controls. The effect of CPAP treatment on metabolic syndrome and insulin resistance assessed by homeostatic model assessment index was investigated Results: It has been observed that the body mass index (BMI) decreases significantly following the CPAP treatment. No significant changes were found in the anthropometric measurements including the neck circumference, waist circumference, hip circumference, and waist/hip ratios as well as insulin resistance and metabolic syndrome parameters (before of treatment BMI: 31.33±5.58, post treatment BMI: 30.83±7.13, p=0.03). The ESS evaluating the subjective daytime sleepiness following the CPAP treatment has decreased significantly. Conclusion: Although this study didn't improve insulin resistance with assessed homeostatic model assessment, and metabolic syndrome, a significant improvement in BMI and ESS was demonstrated in post treatment. Long-term studies with more cases and with high compliance are needed to demonstrate the effects of CPAP treatment on metabolic syndrome in OSAS patients. [ABSTRACT FROM AUTHOR]

Background and design: In this study, we aimed to identify whether there was an association of insulin resistance and metabolic syndrome with androgenetic alopecia (AGA) in reproductive women. Materials and methods: We investigated insulin resistance and metabolic syndrome, which is known to be associated with insulin-resistance, in 55 females with AGA (Ludwig I and above) who were under 45 years of age and 50 age-matched woman without AGA. We used homeostasis model assessment (HOMA) index and quantitative insulin sensitivity check index (QUICKI) to identify insulin resistance. The cut-off value for HOMA was accepted as 2.7. The diagnosis of metabolic syndrome was established using the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria. Results: Serum fasting blood glucose levels were significantly higher in females with AGA than in controls (p<0.05). According to HOMA index, insulin resistance was determined in 11 of 55 (20%) patients in the AGA group, whereas it was identified in only 6 of 50 (12%) controls. The difference between the two groups was not statistically significant (p>0.05). The two groups were also compared for the levels of QUICKI. The mean levels of QUICKI in patient control groups were 0.36±0.04 and 0.36±0.03, respectively. The difference between the groups was not statistically significant (p>0.05). Finally, when the two groups were assessed according to the NCEP ATP III-criteria, metabolic syndrome was identified in 5 out of the 55 (9.1%) patients in the AGA group whereas none of participants had metabolic syndrome in control group. The difference between these groups was not statistically significant (p>0.05). Conclusion: In our study, it was shown that there was no significant relationship of insulin resistance and metabolic syndrome with AGA in women. (Turkderm 2015; 49: 134-8) [ABSTRACT FROM AUTHOR]